Connor Clark & Lunn Investment Management Ltd. bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 29,146 shares of the company's stock, valued at approximately $461,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.07% of Keros Therapeutics as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after buying an additional 577,220 shares during the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after acquiring an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Keros Therapeutics by 112.3% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock valued at $24,493,000 after purchasing an additional 223,155 shares in the last quarter. FMR LLC grew its holdings in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Finally, Holocene Advisors LP grew its holdings in shares of Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock valued at $48,959,000 after purchasing an additional 154,784 shares during the last quarter. Institutional investors own 71.56% of the company's stock.
Analyst Ratings Changes
KROS has been the topic of a number of research analyst reports. Oppenheimer cut their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. HC Wainwright reduced their price objective on Keros Therapeutics from $47.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Piper Sandler lowered their target price on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Truist Financial cut their price target on Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a research note on Monday, December 23rd. Finally, Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $42.33.
Check Out Our Latest Research Report on KROS
Keros Therapeutics Price Performance
Shares of Keros Therapeutics stock traded down $0.28 during midday trading on Wednesday, reaching $11.01. The company had a trading volume of 493,282 shares, compared to its average volume of 678,213. The stock has a fifty day moving average price of $11.13 and a 200 day moving average price of $35.22. Keros Therapeutics, Inc. has a fifty-two week low of $9.78 and a fifty-two week high of $72.37. The firm has a market cap of $446.59 million, a PE ratio of -2.11 and a beta of 1.39.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.
Keros Therapeutics Profile
(
Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
